LetterLetter
Rheumatoid Arthritis Known HLA Associations are Unlikely To Be Associated With Atopic Dermatitis
David J. Margolis, Nandita Mitra and Dimitri S. Monos
The Journal of Rheumatology October 2020, jrheum.200583; DOI: https://doi.org/10.3899/jrheum.200583
David J. Margolis
Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania; Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. This work was supported in part by grants from the National Institutes for Health (NIAMS) R01-AR060962 (PI: Margolis) and R01-AR070873 (MPI: Margolis/Monos). The Pediatric Eczema Elective Registry (PEER) study is funded as the Atopic Dermatitis Registry by Valeant Pharmaceuticals International (PI: Margolis). D.J. Margolis is or recently has been a consultant for Pfizer, Leo, and Sanofi with respect to studies of atopic dermatitis and serves on an advisory board for the National Eczema Association. D.S. Monos is Chair of the Scientific Advisory Board of Omixon, and owns options in and receives royalties from Omixon. Address correspondence to Dr. D.J. Margolis, MD, PhD, 901 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104, USA. Email: margo@pennmedicine.upenn.edu.
Nandita Mitra
Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania; Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. This work was supported in part by grants from the National Institutes for Health (NIAMS) R01-AR060962 (PI: Margolis) and R01-AR070873 (MPI: Margolis/Monos). The Pediatric Eczema Elective Registry (PEER) study is funded as the Atopic Dermatitis Registry by Valeant Pharmaceuticals International (PI: Margolis). D.J. Margolis is or recently has been a consultant for Pfizer, Leo, and Sanofi with respect to studies of atopic dermatitis and serves on an advisory board for the National Eczema Association. D.S. Monos is Chair of the Scientific Advisory Board of Omixon, and owns options in and receives royalties from Omixon. Address correspondence to Dr. D.J. Margolis, MD, PhD, 901 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104, USA. Email: margo@pennmedicine.upenn.edu.
Dimitri S. Monos
Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania; Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. This work was supported in part by grants from the National Institutes for Health (NIAMS) R01-AR060962 (PI: Margolis) and R01-AR070873 (MPI: Margolis/Monos). The Pediatric Eczema Elective Registry (PEER) study is funded as the Atopic Dermatitis Registry by Valeant Pharmaceuticals International (PI: Margolis). D.J. Margolis is or recently has been a consultant for Pfizer, Leo, and Sanofi with respect to studies of atopic dermatitis and serves on an advisory board for the National Eczema Association. D.S. Monos is Chair of the Scientific Advisory Board of Omixon, and owns options in and receives royalties from Omixon. Address correspondence to Dr. D.J. Margolis, MD, PhD, 901 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104, USA. Email: margo@pennmedicine.upenn.edu.
Abstract
Individuals with atopic dermatitis (AD) frequently have illnesses such as asthma and seasonal allergies. Recent studies have revealed associations between AD and rheumatoid arthritis (RA)1,2. For example, a study from Germany showed an increased risk of RA for those with AD (risk ratio 1.72, 95% CI 1.25–2.37).
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Rheumatoid Arthritis Known HLA Associations are Unlikely To Be Associated With Atopic Dermatitis
David J. Margolis, Nandita Mitra, Dimitri S. Monos
The Journal of Rheumatology Oct 2020, jrheum.200583; DOI: 10.3899/jrheum.200583